US EditionFDA approves new drug to treat protein buildup in the heart
- The U.S. Food and Drug Administration has approved Amvuttra, a drug developed by Alnylam Pharmaceuticals, for treating transthyretin amyloid cardiomyopathy , which affects many individuals.
- In clinical studies, Amvuttra reduced the risk of death and heart issues by 28% over three years compared to a placebo.
- Amvuttra costs approximately $476,000 per year, which may limit access for patients with Medicare Advantage plans, as expressed by Alnylam CEO Yvonne Greenstreet.
- There is significant unmet need in the market for this treatment, according to healthcare analyst Dr. Mani Foroohar.
Insights by Ground AI
Does this summary seem wrong?
27 Articles
27 Articles
All
Left
1
Center
8
Right
1
FDA approves new drug to treat protein buildup in the heart
The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals and is used to treat protein buildup in the heart
·Washington, United States
Read Full Article
InsideNoVA.com+20 Reposted by 20 other sources
FDA OKs Amvuttra To Treat Heart Conditions
Key Takeaways
Coverage Details
Total News Sources27
Leaning Left1Leaning Right1Center8Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
C 80%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
